Psilocybin and Meaning-Making at End of Life

Psilocybin & Anxiety

70% rated it among the most meaningful events of their lives

70% of cancer patients in the NYU psilocybin trial rated a single session among the five most personally meaningful experiences of their entire lives. At 4.5-year follow-up, 71% still said so.

Ross et al., Journal of Psychopharmacology, 2016; Agin-Liebes et al., 2020

-5.78

mean reduction in loss-of-meaning score at 3 months in cancer patients who received psilocybin (Ross et al., ACS Pharmacology, 2021)

3 themes

from 7 UK cancer patients in Khan 2026: reconciliation with death, cancer's place in life, and confidence in facing recurrence

4.5 years

duration over which meaning and emotional benefits persisted in the NYU trial long-term follow-up (Agin-Liebes et al., 2020)

Ross et al., Journal of Psychopharmacology, 2016; Agin-Liebes et al., 2020

View as image ↗

Seventy percent. That is the number of cancer patients in the NYU psilocybin trial who rated a single session among the five most personally meaningful experiences of their entire lives. Many of them were at end of life, facing terminal diagnoses. They had lived through everything life had given them, decades of relationships, achievements, and losses. And they rated a psilocybin session alongside those decades.^[1]

That finding was not a passing anecdote. It came from validated rating scales administered in a formal randomized controlled trial. When Agin-Liebes and colleagues followed up with the same patients 4.5 years later, 71% still said so.^[2]

This article covers what that statistic means: why psilocybin produces meaning specifically at end of life, how researchers measure it, and how long it lasts. The clinical evidence base for anxiety and depression reduction in terminal cancer patients is covered in the guide to psilocybin for cancer patients. This article focuses specifically on the meaning research.

The 70% Statistic — What It Actually Measured

The number is striking. But what it measured is more important than the number itself.

In Ross and colleagues' 2016 NYU trial, 29 cancer patients received either a high-dose psilocybin session or a niacin comparison session, with the groups crossing over. Researchers used validated instruments — including the Mystical Experience Questionnaire and standardized clinical rating scales — to measure not just anxiety and depression outcomes, but subjective experience quality.^[1]

Participants were asked whether the psilocybin session ranked among the most personally meaningful events of their entire lives. Seventy percent said yes. Sixty percent said it was the single most spiritually significant experience they had ever had. These are not descriptions of an interesting drug experience. They are ratings of meaning in the context of a full human life, made by people who were dying and who had decades of life behind them to compare against.^[1]

The Hopkins trial from the same year — Griffiths and colleagues, 51 cancer patients in a crossover design — measured similar outcomes. Increases in quality of life, life meaning, and optimism were among the most consistent findings at 6-month follow-up.^[3]

The 4.5-year follow-up by Agin-Liebes and colleagues tracked 14 participants from the NYU cohort. The remarkable finding was not just that anxiety and depression improvements held (60-80% still met clinical response criteria), but that 71% still rated the psilocybin session among the most personally meaningful experiences of their lives — at the same high rate as they had immediately after treatment. The meaning rating did not fade with time the way the novelty of an experience typically does.^[2]

This durability distinguishes the finding from drug-induced euphoria, which typically fades as the acute effects resolve. Something about the session experience left a lasting mark on how these patients understood their lives, even years after the session itself.

Why Psilocybin Produces Meaning — The Mystical Experience Mechanism

The mechanism that makes psilocybin different from conventional treatments for end-of-life distress is not its effect on serotonin or anxiety pathways. It is what it does to the experience of the self.

Griffiths and colleagues documented this in 2006, years before the cancer trials, in a landmark study of 36 healthy volunteers who received high-dose psilocybin in a controlled setting.^[4] The sessions produced mystical-type experiences characterized by specific measurable dimensions: unity (the sense of oneness with all things, dissolving the boundary between self and not-self), transcendence (going beyond personal identity and ordinary time and space), and sacredness (encountering something experienced as sacred or holy). Two months later, participants continued to rate the session among the most personally meaningful and spiritually significant events of their lives. Well-being had improved and stayed improved.^[4]

The critical finding was that mystical experience quality predicted the magnitude of these improvements. It was not "having taken psilocybin" that produced the lasting benefit. It was the degree to which the person experienced unity and transcendence during the session.

This mechanism matters for understanding end-of-life meaning specifically. For a person who is dying, the dominant experience is often one of narrowing: the self is contracting around the disease, the prognosis, the losses. Conventional therapy can work with the thoughts and emotions associated with this contraction. What psilocybin does, when it produces a full mystical experience, is temporarily dissolve the self-boundary that defines that contraction. The sense of "I am this body with this cancer" expands into something larger. The disease does not disappear, but the identity is no longer defined by it alone.

The Griffiths 2016 Hopkins trial extended this to cancer patients directly. Fifty-one patients in a crossover RCT received either high-dose psilocybin (22-30 mg per 70 kg of body weight) or a very low dose. At 6 months, 78% showed clinically significant depression reduction and 83% showed clinically significant anxiety reduction. Life meaning, optimism, and spiritual well-being all increased significantly. Mystical experience intensity during the session predicted the magnitude of these improvements at 6 months.^[3]

The mechanism, then, is not pharmacological in the conventional sense. Psilocybin does not simply suppress distressing symptoms the way a sedative or antidepressant would. It creates a specific kind of experience — one that a substantial portion of terminal cancer patients rate as among the most meaningful events of their lives — and that experience is what produces the lasting shift.

The Loss-of-Meaning Data — What Ross 2021 Found

The most precise measurement of psilocybin's effect on meaning specifically comes from a secondary analysis of the NYU trial published by Ross and colleagues in 2021.

The primary outcome of the original 2016 trial was anxiety and depression. Ross 2021 re-analyzed the data for two specific outcomes that get less attention: loss of meaning, and suicidal ideation. Both are clinically critical in end-of-life populations and both represent something more fundamental than anxiety or depression scores.^[5]

The loss-of-meaning finding: participants showed a mean reduction in loss-of-meaning score of 5.78 points (standard deviation 6.01) at the 3-month follow-up. Loss of meaning — the clinical sense that life has no point, that the self is fragmented, that existence is empty — is distinct from depression as psychiatry typically defines it. A patient can score in the moderate depression range without feeling that their life is meaningless, and a patient with apparently mild mood scores can be profoundly demoralized. The 5.78-point reduction reflects a specific change in that dimension, not just a broadening of depressive symptoms.^[5]

The suicidal ideation finding is more striking for its speed. Suicidal ideation decreased significantly within 8 hours of treatment, well before any conventional antidepressant would be expected to take effect. That reduction was sustained at 3.2-year and 4.5-year follow-up. The rapid onset suggests psilocybin does not work through gradual neurobiological adaptation. Something in the session experience itself appears to change the relationship with living and dying, quickly enough to affect passive suicidal ideation within a single day.^[5]

Ross and colleagues' 2025 Phase 2b randomized controlled trial — the most recent formal RCT from the group that ran the original 2016 study — replicated these findings in a new cohort. Patients with life-threatening illness who received psilocybin-assisted therapy showed significantly greater reductions in depression, anxiety, demoralization, death anxiety, and hopelessness compared to the placebo group. Spiritual well-being and quality of life also improved significantly.^[6]

The companion piece on psilocybin and demoralization covers the demoralization angle in more depth, including the PATH hospice trial, which targeted demoralization specifically as a primary outcome in terminally ill patients.

What Patients Say — Three Themes from Khan 2026

Clinical scales measure what researchers decide to measure. Qualitative research captures what patients experience in their own words, which is often different.

Khan and colleagues published a 2026 interpretative phenomenological analysis of seven UK women living with cancer-related existential distress who had participated in psilocybin-assisted therapy. The women described their sessions as immersive rather than observed — not watching an experience from the outside but inhabiting it fully. Three core themes emerged from the analysis.^[7]

The first was reconciliation with death. Not resigned acceptance of something terrible, and not denial of what is coming. Reconciliation in the sense of coming to terms with death as part of the structure of life rather than as an enemy that has been lost to. One participant described facing death not as something approaching from outside but as something already present in the fabric of her situation that she could now see clearly without being overwhelmed by it.^[7]

The second theme was acknowledgment of cancer's place in life. The disease was not erased or minimized. It was integrated. Participants found a way to hold the cancer diagnosis within a larger understanding of their lives rather than allowing it to define the totality of who they were. "Cancer found its place" captures the theme: not cancer found a cure, not cancer was defeated — cancer found a position in the larger story of the self that did not require the person to organize their entire remaining life around the disease.

The third theme was confidence in the face of cancer recurrence. The fear of the cancer coming back — or progressing — is one of the most psychologically consuming aspects of advanced cancer. Participants described a changed relationship with that fear: not an absence of it, but a sense that they could face recurrence without being destroyed by the anticipation of it.^[7]

D'Angelo and colleagues' 2025 qualitative study of 15 cancer patients in the United States found that the advanced cancer diagnosis itself creates a distinctive kind of openness to psilocybin therapy. Patients facing existential crisis tend to approach psilocybin differently than patients in earlier stages, for whom it remains one treatment option among others. When conventional medicine has no more to offer for existential despair, patients become willing to try something that could fundamentally change how they understand their situation.^[8]

Magnani and colleagues' 2026 narrative review proposed "psycho-existential distress" as a more precise clinical description of what psilocybin-assisted therapy addresses in advanced cancer. The term acknowledges that end-of-life distress is simultaneously psychological — measurable with standard instruments, amenable to clinical intervention — and existential, concerned with meaning, identity, and finitude in ways that depression and anxiety ratings alone do not capture.^[9]

The "psycho-existential" framing shifts the clinical question from "can we reduce anxiety scores?" to "can we change how a person relates to their own mortality?" The answer, from both the quantitative and qualitative evidence, is yes — and the change is often experienced as meaningful rather than merely therapeutic.

How Long the Meaning Lasts — The Durability Evidence

Most therapeutic effects in medicine fade. Antidepressants require ongoing use to sustain their effects. Brief psychotherapy shows benefits that attenuate over time without booster sessions. The 4.5-year follow-up data from the NYU trial suggests psilocybin's effect on meaning does something different.

Agin-Liebes and colleagues traced 14 participants from the 2016 Ross trial and found that between 60 and 80% still met response criteria for anxiety and depression at the follow-up point. More strikingly, 71% still rated the psilocybin session among the five most personally meaningful experiences of their entire lives. Demoralization, hopelessness, and death anxiety remained significantly reduced compared to baseline.^[2]

This is a 4.5-year persistence in a population in which many participants were not expected to survive 4.5 years. The cohort that could be followed up represents the survivors. That selection may affect the interpretation, but it does not explain the continued high rating of the experience as personally meaningful. Survivors have continued living for years and accumulating new experiences against which to compare the session. The rating held nonetheless.

Agrawal and colleagues' 2025 Cancer cohort study in depressed cancer patients found that single-dose psilocybin benefits persisted long-term. The single-session model is clinically critical in palliative care: patients may not survive for multiple treatment sessions, and the therapy system cannot be designed around multi-session protocols that presuppose ongoing patient availability.^[10] That single doses can produce lasting benefit removes a structural barrier to delivering this treatment to patients who may have limited time.

The companion piece on how psilocybin changes the relationship with mortality covers the death-attitude change data in more depth, including the Sweeney 2022 finding that psychedelic experiences produce similar shifts in death attitudes as near-death experiences.

For readers interested in the practical and ethical dimensions of delivering psilocybin in palliative settings, the companion piece on psilocybin in palliative care: research and ethics covers what the Dorval 2025 roadmap and the current regulatory landscape mean for access. For a detailed account of the landmark 2016 trials that generated much of this data, the companion piece on psilocybin and end-of-life anxiety: the NYU and Hopkins trials covers the coordinated design and full results of both studies.

The Bottom Line

Cancer patients at end of life consistently rate psilocybin sessions among the most personally meaningful events of their lives, a finding that holds at 4.5-year follow-up. Ross 2021's secondary analysis documented a mean 5.78-point reduction in loss-of-meaning scores at 3 months, with suicidal ideation decreasing within 8 hours. The mechanism runs through mystical experience: psilocybin's capacity to temporarily dissolve the self-boundary allows the disease to be integrated into a larger narrative rather than defining the totality of who the patient is. Qualitative data from UK cancer patients identifies three themes: reconciliation with death, integration of the diagnosis, and confidence facing recurrence.

Frequently Asked Questions

Can psilocybin give dying people a sense of meaning?

The clinical evidence consistently shows yes. In the NYU randomized controlled trial (Ross et al., 2016, n=29), 70% of cancer patients rated the psilocybin session among the five most personally meaningful experiences of their entire lives. A 4.5-year follow-up (Agin-Liebes et al., 2020) found 71% still saying so, alongside sustained reductions in demoralization and hopelessness. The Ross 2021 secondary analysis measured a mean 5.78-point reduction in loss-of-meaning scores at 3 months. These are not anecdotes — they are measured outcomes from formal clinical trials using validated rating scales.

How does psilocybin affect spiritual beliefs in terminal patients?

Psilocybin does not install or modify specific spiritual beliefs. It produces mystical-type experiences — characterized by unity, transcendence, and sacredness — that shift how people understand their relationship to mortality. Griffiths and colleagues' foundational 2006 study established that mystical experience quality predicts the magnitude of sustained well-being improvements, and subsequent cancer trials confirmed the same pattern. In the Hopkins 2016 trial (n=51), increases in spiritual well-being and life meaning at 6 months were among the most consistent outcomes, and mystical experience intensity during the session predicted those improvements.

Does psilocybin help with acceptance of death?

Qualitative research from Khan et al. (2026) with seven UK cancer patients found that "reconciliation with death" was one of three central themes patients described after psilocybin sessions. Reconciliation in their accounts meant coming to terms with death as part of the structure of life, rather than an external threat to be resisted. Separately, Sweeney 2022 found that approximately 90% of psychedelic users reported being less afraid of death after their experiences, comparable to the shifts reported after near-death experiences. The Hopkins and NYU cancer trials measured death anxiety directly and found significant reductions that persisted at multi-year follow-up.

What do cancer patients say about psilocybin experiences?

Patients in the NYU trial described the session as among the most personally meaningful experiences of their lives. Khan 2026's qualitative analysis identified three recurring themes: reconciliation with death (not resignation but active acceptance), acknowledgment of cancer's place in life (the diagnosis integrated into a larger self-narrative rather than defining it), and confidence in facing the prospect of cancer recurrence. D'Angelo 2025 found that advanced cancer patients approach psilocybin differently than earlier-stage patients — existential crisis creates a kind of readiness that makes the session more transformative rather than merely interesting.

How long do psilocybin's effects on meaning last?

The longest available data is from Agin-Liebes and colleagues' 4.5-year follow-up of the NYU trial. At that point, 71% of participants still rated the psilocybin session among the five most personally meaningful experiences of their lives, and 60-80% still met clinical response criteria for anxiety and depression. The Ross 2021 secondary analysis tracked loss-of-meaning reductions and suicidal ideation through 4.5 years, finding sustained effects throughout. Agrawal et al.'s 2025 Cancer study found that single-dose psilocybin produced long-term benefits in depressed cancer patients, supporting the durability of the single-session model in palliative care contexts.

Sources & References

1. 1RTHM-00445·Ross, Stephen et al. (2016). “Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
2. 2RTHM-01160·Agin-Liebes, Gabrielle I et al. (2020). “Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
3. 3RTHM-00426·Griffiths, Roland R et al. (2016). “Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
4. 4RTHM-00096·Griffiths, R R et al. (2006). “Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance..” Psychopharmacology.Study breakdown →PubMed →↩
5. 5RTHM-01425·Ross, Stephen et al. (2021). “Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer..” ACS pharmacology & translational science.Study breakdown →PubMed →↩
6. 6RTHM-00949·Ross, Margaret L et al. (2025). “Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial..” General hospital psychiatry.Study breakdown →PubMed →↩
7. 7RTHM-02235·Khan, Zaynab et al. (2026). “Sense-Making Around Psilocybin in UK Women Experiencing Cancer-Related Existential Distress: An Interpretative Phenomenological Analysis..” Qualitative health research.Study breakdown →PubMed →↩
8. 8RTHM-02072·D M Schuman, Haley et al. (2025). “"Facing Death. . . Now, That's a Serious Thing to Confront" A Qualitative Analysis of Patient Perspectives on Psychedelic-Assisted Therapy for Cancer-Related Psychosocial Symptoms..” Integrative cancer therapies.Study breakdown →PubMed →↩
9. 9RTHM-02236·Magnani, Luca et al. (2026). “Psilocybin-assisted psychotherapy for psycho-existential distress in advanced cancer: a narrative review..” BMJ supportive & palliative care.Study breakdown →PubMed →↩
10. 10RTHM-02045·Agrawal, Manish et al. (2025). “Long-term benefits of single-dose psilocybin in depressed patients with cancer..” Cancer.Study breakdown →PubMed →↩